JANX011 / Janux Therapeutics - LARVOL DELTA

Initial clinical data from the Phase 1 healthy volunteer study of JANX011 expected to be announced in the second half of 2026 (Businesswire)

P1 data • Immunology

Upcoming Milestones (Businesswire) - "(i) Janux expects to provide additional clinical data for JANX007 at a future medical congress in the first half of 2027; (ii) Janux plans to announce an initial clinical update from the Phase 1 study of JANX011 in healthy volunteers in the second half of 2026; (iii) Janux plans to initiate clinical development of JANX013, a PSMA-targeted CD28 costimulatory TRACIr, in the second half of 2026."

New trial • P1 data • Castration-Resistant Prostate Cancer

Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Janux Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Immunology

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 (Businesswire) - "The Phase 1 study (NCT07291323) is an open-label, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JANX011 in healthy adult volunteers."

Trial status • Immunology

Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Janux Therapeutics

New P1 trial • Immunology